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Abstract
Rationale It has been reported that in panic disorder (PD),
tryptophan depletion enhances the vulnerability to experi-
mentally induced panic, while the administration of
serotonin precursors blunts the response to challenges.
Objectives Using a high-dose carbon dioxide (CO2)c h a l -
lenge, we aimed to investigate the effects of acute tryptophan
depletion (ATD) and acute tryptophan loading (ATL) on
CO2-induced panic response in healthy volunteers.
Methods Eighteen healthy volunteers participated in a
randomized, double-blind placebo-controlled study. Each
subject received ATD, ATL, and a balanced condition
(BAL) in separate days, and a double-breath 35% CO2
inhalation 4.5 h after treatment. Tryptophan (Trp) manipu-
lations were obtained adding 0 g (ATD), 1.21 g (BAL), and
5.15 g (ATL) of l-tryptophan to a protein mixture lacking
Trp. Assessments consisted of a visual analogue scale for
affect (VAAS) and panic symptom list. A separate analysis
on a sample of 55 subjects with a separate-group design has
also been performed to study the relationship between
plasma amino acid levels and subjective response to CO2.
Results CO2-induced subjective distress and breathlessness
were significantly lower after ATD compared to BAL and
ATL (p<0.05). In the separate-group analysis, ΔVAAS
scores were positively correlated to the ratio Trp:ΣLNAA
after treatment (r=0.39; p<0.05).
Conclusions The present results are in line with preclinical
data indicating a role for the serotonergic system in
promoting the aversive respiratory sensations to hypercap-
nic stimuli (Richerson, Nat Rev Neurosci 5(6):449–461,
2004). The differences observed in our study, compared to
previous findings in PD patients, might depend on an
altered serotonergic modulatory function in patients com-
pared to healthy subjects.
Keywords Anxiety.Panic.Stress.5-HT.Hypercapnia.
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Respiration
Introduction
In patients affected by panic disorder (PD), acute trypto-
phan depletion (ATD) enhances the response to a number of
panicogenic agents. This effect of ATD has been shown in
studies which used inhalation of 35% and 5% carbon
dioxide (CO2) (Miller et al. 2000; Schruers et al. 2000) and
infusion of flumazenil (Bell et al. 2002; Davies et al. 2006)
as challenges to induce panic, but no effect has been
observed using infusion of cholecystokinin tetrapeptide
(CCK-4) (Toru et al. 2006). Pre-treatment with 5-
hydroxytryptophan (5-HTP), the immediate precursor of
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DOI 10.1007/s00213-011-2177-8serotonin (5-HT), has been shown to blunt the response to
35% CO2 challenge, indicating a “protective” effect on
experimentally induced panic (Schruers et al. 2002b). These
findings seem to indicate that in PD patients, fear or anxiety
provoked by some panicogenic challenges is negatively
correlated to the availability of 5-HT precursors.
Studies in healthy volunteers yielded inconclusive
findings: reports showed that ATD failed to modify the
panicogenic effects of CCK-4 (Koszycki et al. 1996)a s
well as the effects of 5% CO2 inhalation (Miller et al. 2000)
or the Read rebreathing test (Struzik et al. 2002). Two
studies have tested the effects of 35% CO2 in tryptophan
(Trp) depleted subjects, one showing an increase of CO2-
induced neurovegetative symptoms but not subjective
anxiety (Klaassen et al. 1998), while the other did not find
any significant difference between ATD condition and
placebo with regard to CO2-provoked subjective effects
(Hood et al. 2006). Administration of 5-HTP in healthy
volunteers was shown to reduce CCK-4-induced panic
attacks and panic-related cognitive symptoms, specifically
in females (Maron et al. 2004), but had no effects on the
response to CO2 (Schruers et al. 2002b).
The discrepancies observed between PD patients and
healthy controls, in terms of the effects of ATD on the
subjective response to challenges might be due to the relative
low sensitivity exhibited by healthy subjects to panicogenic
agents. We have previously showed in healthy volunteers that
the inhalation of CO2 dose-dependently induces panic-like
symptoms, and that high doses of CO2 (double-breath of
35% CO2) in healthy subjects might be as effective as
moderate doses of CO2 are in PD patients (Griez et al. 2007;
Schruers et al. 2004b). Here, we intended to perform a study
in healthy subjects using a high-dose CO2 challenge in order
to test whether we can reproduce in a non-clinical population
the same modulating effects of 5-HT manipulation observed
in PD patients on experimental panic response; for this
purpose, we investigated the effects of ATD on CO2-induced
panic response in healthy volunteers.
Additionally, since the Trp suppletion studies with
panicogenic challenges conducted in healthy subjects gave
inconclusive results (Maron et al. 2004; Schruers et al.
2002b), we also tested the effects of acute tryptophan
loading (ATL) on subjective response to CO2 challenge.
Material and methods
Subjects
Healthy volunteers were recruited among students or staff,
through advertisements from within the Vijverdal Psychi-
atric Hospital Maastricht (Mondriaan Zorggroep) and
throughout the Maastricht University locations. The Med-
ical Ethics Committee of the Academic Hospital Maastricht
and Maastricht University approved the study, and the
subjects were paid for their participation in the experiment.
After a complete description of the study, a written
informed consent was obtained from the subjects. The
volunteers underwent collection of medical history and
physical examination. Inclusion criteria were age between
18 and 65 years and a good present and past physical and
mental condition. The latter was established using a
structured psychiatric interview (Mini International Neuro-
psychiatric Interview) performed by a physician. Exclusion
criteria were current psychopharmacological or psychological
treatment, recent alcohol intake, substance or caffeine-related
disorders, excessive smoking (>10 cigarettes a day),
respiratory or cardiovascular disease, hypertension (dia-
stolic >100 mmHg; systolic >170 mmHg), personal or
family history of cerebral aneurysm, pregnancy, and
epilepsy. Individuals were also excluded if they reported
common specific fears or if they had a history of panic
attacks, or a history of PD in a first-degree relative.
Design
Subjects were randomized in double-blind placebo-
controlled cross-over study design. The subjects received
three different gelatin-based mixtures (GBM) on three
different days in a randomized order, to induce respectively
the ATD condition, a balanced condition (BAL) and the
ATL condition. On each day, after GBM administration,
they underwent a double-breath CO2 challenge.
A separate analysis has been conducted on a larger
sample of subjects in a randomized separate-group design,
in order to investigate the relationship between the ratio Trp
to the sum of large neutral amino acids in plasma
(Trp:ΣLNAA) and the subjective response to CO2. Subjects
were randomly assigned to one of the three groups: ATD
condition, BAL condition, and ATL condition. This sample
also included subjects who were enrolled in the cross-over
study for which only the first study day was taken into
consideration in the analysis.
Procedure
The subjectsarrived atthe clinicafter anovernight fast.Blood
was drawn to measure plasma Trp and large neutral amino
acids (LNAA)levels.GBM were administeredinthe morning
at about 9:30. After drinking the GBM, the subjects remained
on the ward and were allowed to read or watch a nature
documentary on video. Subjects had ad libitum access to
mineral water, but they were asked to refrain from eating
and drinking any xanthine beverages. At 4.5 h after
GBM administration, other blood samples were collected
to monitor plasma Trp and LNAA levels. Ten minutes
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of a gas mixture containing 35% CO2 and 65% O2.
Gelatin-based mixtures
The gelatin consists of a hydrolysate collagen-protein
comprising the entire range of amino acids in the form of
peptides, but completely lacking Trp. After administration,
these peptides are decomposed into amino acids, and the
mechanism of depletion is identical to that of the “classic”
amino acid mixture (Sambeth et al. 2009). The GBM was
kindly provided by PB Gelatins (Tessenderlo Group,
Belgium) in form of powder. Amino acid composition of
the GBM can be found in Table 1. The drink was prepared
mixing 100 g of the powder with 200 ml water at 50–70°C.
The drink was kept refrigerated at 4°C and then kept at
room temperature for 30 min before administration. The
three GBM were identical in composition, except that
1.15 g of l-tryptophan and 5.15 g of l-tryptophan was added
to the mixtures for the BAL and ATL conditions,
respectively. No l-tryptophan was added for the ATD
condition. The three GBM had the same color and taste.
Carbon dioxide challenge
The 35% CO2-inhalation procedure was performed in
accordance to a standardized protocol developed at the
Maastricht Academic Anxiety Center (Griez et al. 1987;
Griez and Schruers 1998). A gas mixture containing 35%
CO2/65% O2 was delivered through a nasal–oral exercise
self-administration facemask, using a double vital capacity
inhalation technique. Before the challenge, the inspired
vital capacity of every subject was measured using an
analogue respirometer (Wright respirometer Mark 20)
connected to the self-administration mask. The same
respirometer measured the gas volume delivered at each
inhalation. The inspired vital capacity with a double breath
of air was measured on each occasion, and a challenge was
considered adequate if it was more than 80% of the baseline
vital capacity. The subjects were then given the self-
administration mask and asked to exhale as deeply as
possible. They were asked to take a maximal inspiration
through the mask and to make a complete expiration
outside the mask, immediately followed by a second
maximal inspiration. At the end of the second inhalation,
the subjects were asked to hold their breath for 4 s to
enhance the alveolar gas exchange, and finally make a
complete expiration outside the mask again.
Amino acid analysis
Samples for determination of plasma amino acid levels
were taken at baseline (T0) and 4.5 h after GBM
administration (T1). Blood (10 ml) was collected by
venepuncture in sodium heparin tubes at each time point
immediately after the rating of subjective assessments.
After collection, the blood samples were immediately
centrifuged at 4°C (10 min at 4,000 rpm). Subsequently,
100 μl of plasma was mixed with 8 mg of sulphasalicyl
acid and frozen at −80°C until the amino acid analysis was
performed (van Eijk et al. 1993). Plasma amino acids were
determined using a fully automated high-performance
liquid chromatography system after precolumn derivatiza-
tion with o-phthaldialdehyde (OPA). OPA-AA derivates of
the amino acids were quantified with fluorescence detec-
tion. The concentrations of plasma amino acids were
expressed as micromoles per liter (μmol/l) (van Eijk et al.
1993). The ratio of total Trp:ΣLNAA (LNAA, i.e.,
tyrosine, phenylalanine, leucine, isoleucine, and valine) at
baseline and 4.5 h after GBM were used as endpoints to
monitor changes in Trp availability.
Assessments
Rating scales to assess panicogenic effects of CO2
challenge were chosen with reference to the definition of
panic attack in DSM-IV TR diagnostic criteria (APA 2000).
We used a visual analogue scale for affect (VAAS)
labeled “fear or discomfort”, ranging from 0 (no fear/
discomfort at all) to 100 (the worst imaginable fear/
discomfort). The participants were instructed to indicate
Table 1 Amino acid spectrum
Amino acid spectrum (typical weight% on ds protein)
Alanine 8.4
Arginine 7.7
Aspartic acid/asparagine 4.5
Cysteine 0.0
Glutamic acid/glutamine 10.0
Glycine 23.3
Histidine 0.9
Hydroxylysine 1.5
Hydroxyproline 12.3
Isoleucine 1.2
Leucine 2.6
Lysine 3.3
Methionine 0.9
Phenylalanine 1.6
Proline 13.7
Serine 3.4
Threonine 1.9
Tryptophan 0.0
Tyrosine 0.6
Valine 2.2
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feeling either fear or discomfort following an established
procedure (Colasanti et al. 2008).
Panic symptoms were evaluated using the Panic Symp-
tom List (PSL-IV) (Schruers et al. 2000). This consists of a
questionnaire listing 13 items, each representing one of the
DSM-IV TR symptoms (i.e., palpitations; sweating; trem-
bling; sensations of shortness of breath or smothering;
feeling of choking; chest discomfort; nausea or abdominal
distress; feeling dizzy, lightheaded, or faint; derealization or
depersonalization; fear of losing control; fear of dying;
paresthesias; chills or hot flushes). The participants were
asked to rate the intensity of each symptom from 0 (absent) to
4 (very intense). The total scores thus ranged from 0 to 52.
VAAS and PSL-IV were administered at baseline (T0;
pre-GBM administration), 1.5 h (T1), 3 h (T2), 4.5 h post-
GBM administration (T3), and after CO2 challenge (Post-
CO2). Post-CO2 scores indicated the worst moment
experienced by the subjects after inhaling the gas mixture.
Mood states were measured with the shortened 32-item
validated version of the Dutch translation of the Profile of
Mood States Scale (POMS) (Wald and Mellenbergh 1990),
which consists of five mood scales (depression, tension/
anxiety, vigor, anger/hostility, and fatigue). The POMS was
administered at T0, T1, T2, and T3. Subjects were asked to
rate the scale according to how they felt at that moment.
Data analysis
All the data are presented as mean ± standard deviation
(SD). Percentage changes in Trp: ΣLNAA ratio (Δ%
Trp:ΣLNAA ratio) after GBM (T3) compared to baseline
(T0) were calculated by the formula T3-T0/T0×100. CO2-
induced changes in VAAS and PSL scores were expressed
as Δ scores (obtained by the formula POST-CO2 scores−
T3 scores). In the cross-over sample, all data were analyzed
with analysis of variance (ANOVA) for repeated measures
with time and treatment condition as within-subjects
factors. The effects of time X treatment condition interac-
tion were studied to investigate the influence of GBM
condition (ATD, BAL, ATL) on the subjective response to
CO2 measured with VAAS and PSL scores. The analysis of
VAAS scores has been repeated after controlling for gender,
and the interaction time X treatment condition X gender has
been studied using ANOVA per repeated measures.
To investigate the influence of GBM conditions on
POMS scores, the effects of time per se and time X
treatment condition interaction were studied with ANOVA
per repeated measures.
If indicated by a significant ANOVA condition effect,
time effect, or time X condition interaction effect, a
subsequent evaluation on difference between individual
conditions and between individual time points was done by
within-subject repeated contrasts. The level of significance
was set at 0.05. For the separate-group analysis the
principal statistical analysis consisted of Spearman's non-
parametric correlation between ΔVAAS scores and
Trp:ΣLNAA levels. A partial correlation analysis between
these two variables was repeated after controlling for
gender. Moreover, baseline differences between treat-
ments/groups were analyzed by one-way ANOVA for
continuous variables (age, weight, Trp:ΣLNAA ratio,
VAS, and PSL scores) and chi-square for non-parametric
variables (gender distribution).
Results
Eighteen healthy volunteers (10 male) completed the cross-
over study (mean age 25±5.5 years).
One subject was excluded because she reported nausea
and vomiting after the administration of GBM.
Amino acid levels
Plasma amino acid levels are presented in Fig. 1. Total
Trp:ΣLNAA ratio at T0 did not significantly differ between
treatment conditions (F=0.88,p=0.42). A significant time
X condition interaction was found with Δ%T r p : ΣLNAA
ratio (from T0 to T3) being different between conditions
(F=106.6; p<0.0001). ATD resulted in a decrease of
61.35±15.6% in Trp:ΣL N A Ar a t i oc o m p a r e dt ob a s e l i n e ,
while ATL resulted in an increase of 361.53±154.05%. A
17.76±19% post-GBM increase was found in the BAL
condition. Within-subject contrasts evidenced significant
differences between changes in Trp:ΣLNAA ratio between
ATDandBAL,betweenATLandBAL,andbetweenATDand
ATL (F=106.6; p<0.0001). In three cases of ATD condition,
we observed a decrease in Trp:ΣLNAA ratio <50%, and
in one case of BAL condition, an increase in Trp:
ΣLNAA ratio >50% was observed. For all the other
subjects, we found Trp:ΣLNAA changes >50% in ATD
condition, <50% in balanced condition, >100% in the
ATL condition. The analyses reported in the following
sections have also been performed after exclusion of
those three subjects, obtaining the same results as with
the complete sample.
Subjective measures
VAAS scores (fear/discomfort) between conditions at
different time points, are presented in Fig. 2. There were
no significant differences in VAAS scores at T0, T1, T2,
and T3 between conditions. No effect of GBM administra-
tion per se was observed on VAAS scores, as no significant
difference was found between any of pre-CO2 challenge
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inhalation was followed by an increase in VAAS scores in
all the conditions (F=57.49; p<0.0001). A significant time
X condition interaction was found, indicating that ΔVAAS
scores were significantly lower in ATD compared to BAL
and ATL (33.89±26.18 vs 43.78±25.5 and 44.17±23.88,
respectively; F=5.79 and F=6.58, p<0.05). No significant
differences were found between BAL and ATL conditions.
The findings remained identical after controlling for gender
and no effects of time X gender X condition interaction
have been found.
There were no significant differences in PSL scores
between conditions at any time point. Total PSL scores did
not change at T1, T2, and T3 compared to T0, but
significantly increased after CO2 inhalation, relative to T3
(F=97.51; p<0.0001). ΔPSL scores were similar between
conditions (ATD, 11.11±6.35; BAL, 11.06±4.87; TL,
11.22±4.32; NS). Analyzing individual PSL items sepa-
rately, the only significant effect of treatment conditions on
ΔPSL scores was evident for the item “sensation of
shortness of breath”, indicating that ΔPSL scores after
CO2 were lower in ATD condition than in BAL and ATL
conditions (F=4.11; p<0.05) (Fig. 3).
No order effect was found and ΔVAAS and ΔPSL
scores were not affected by the order of administration of
GBM conditions.
There was a significant effect of time on POMS-vigor (p<
0.0001) and POMS-tension (p<0.05) scores, and within-
subjects contrasts indicated that POMS-vigor scores were
significantly higher at T0 relative to T1 (p<0.01), and
significantly lower at T2 compared to T3 (p<0.01). POMS-
tension scores were higher at T0 compared to T1 (p<0.05).
There was no significant effect of the time X treatment
condition interaction on POMS scores.
Fig. 2 VAAS scores for fear/discomfort at 0, 1.5, 3, 4.5 h after
treatment, and after CO2 inhalation, across treatment conditions.
Acute tryptohan depletion (ATD), balanced condition (BAL), acute
tryptophan loading (ATL); change in VAAS scores was significantly
lower in ATD compared to BAL and ATL (time X condition
interaction: p<0.05)
Fig. 3 Change in PSL scores for shortness of breath after CO2
inhalation relative to T3, across treatment conditions. Acute tryptohan
depletion (ATD), balanced condition (BAL), acute tryptophan loading
(ATL); change in PSL scores was significantly lower in ATD
compared to BAL and ATL (time X condition interaction: p<0.05)
Fig. 1 Plasma Trp:ΣLNAA ratio at baseline and 4.5 h after treatment
across conditions. Acute tryptohan depletion (ATD), balanced condi-
tion (BAL), acute tryptophan loading (ATL); time X condition
interaction: p<0.0001; Trp:ΣLNAA ratio (μmol/l) is presented on
logarithmic scale
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Fifty-five volunteers were enrolled in the separate-group
study. Treatment groups consisted in 19 subjects (8 male;
age: 24.84±5.33 years) in ATD condition, 19 subjects (10
male; age: 23.32±4.46 years) in BAL condition, and 17
subjects (10 male; 24.65±5.32) in ATL condition. Age,
gender distribution, and weight did not significantly differ
between groups. Trp:ΣLNAA ratio at T0 was similar
between conditions and baseline VAAS scores and PSL
scores did not significantly differ between groups either.
The relationship between Trp:ΣLNAA ratio and ΔVAAS
scores is presented in Figs. 4 and 5. ΔVAAS scores were
positively correlated to Δ%T r p : ΣLNAA ratio and
Trp:ΣLNAA ratio at T3 [Spearman's rho=0.395 (p<
0.005) and 0.381 (p<0.005), respectively], indicating that
higher VAAS scores were associated with larger increases
in the ratio Trp:ΣLNAA.
No correlation was found between total PSL scores and
Δ% Trp:ΣLNAA ratio or Trp:ΣLNAA ratio at T3.
Discussion
To investigate whether the amount of available 5-HT
precursors influence the vulnerability to a panicogenic
challenge, we tested the subjective response to a 35%
CO2 inhalation after acute Trp depletion, Trp loading, and
placebo in healthy volunteers. We found a mild, but
significant effect of treatment condition on the subjective
scores of fear/discomfort, indicating that ATD is associated
to a reduced response to a CO2 inhalation relative to
placebo and ATL. The same effect was also evident for
scores on the panic symptom “shortness of breath”. The
analysis of the other separate individual symptoms and the
total composite score of panic symptoms induced by CO2
did not show any significant difference between conditions.
In a separate analysis, we also investigated the relationship
between Trp availability (Trp:ΣLNAA ratio) and subjective
response to CO2, as measured by VAAS scores, in a
separate-group design. We found a relatively weak, but
significant positive correlation between the Trp:ΣLNAA
ratio and CO2-induced changes in VAAS scores, indicating
that lower availability of 5-HT precursors is associated to a
blunted affective response to CO2.
These findings are in contrast with previous results
found in studies by our laboratory (Klaassen et al. 1998;
Schruers and Griez 2004a; Schruers et al. 2000; Schruers et
al. 2002a, b) and in other CO2 challenge studies in healthy
volunteers (Hood et al. 2006) and in PD patients (Miller et
al. 2000). First, we will discuss potential explanations for
the divergent findings observed in this study compared to
other studies with inhaled CO2 and other panicogenic
agents in both healthy volunteers and PD patients.
Furthermore, we will try to interpret our findings in the
context of the complex relationship between panic, 5-HT,
and CO2, also in light of the recent data, which suggest that
Fig. 5 Relationship between Trp:ΣLNAA ratio at T3 (4.5 h post-
treatment) and change in VAAS scores after CO2 inhalation; change in
VAAS scores after CO2 inhalation was positively correlated to
Trp:ΣLNAA ratio at T3 [Spearman's rho=0.381, p<0.005];
Trp:ΣLNAA ratio (μmol/l) is presented on logarithmic scale
Fig. 4 Relationship between% change in Trp:ΣLNAA ratio after
treatment and change in VAAS scores after CO2 inhalation; change in
VAAS scores after CO2 inhalation was positively correlated to%
change in Trp:ΣLNAA ratio [Spearman's rho=0.395, p<0.005]
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concentration. Methodological issues and limitations rela-
tive to the technique used to manipulate 5-HT precursors
will be finally addressed.
Tryptophan depletion/suppletion studies in healthy
volunteers and PD patients
A large body of evidence suggests that manipulation of 5-
HT precursors availability has an influence in modulating
panic and anxiety (see review by Maron et al. 2008).
However, some of the findings from experimental studies,
both in healthy volunteers and PD patients, are divisive and
indicate that the role of 5-HT might not be unique.
Hood et al. (2006) and Klaassen et al. (1998) tested the
effects of ATD on the response to single-breath 35% CO2
challenge in healthy subjects. In a study on 14 healthy
volunteers, no significant differences were found in
subjective measures between ATD and balanced conditions,
although ATD resulted in an increased CO2-induced
elevation of cortisol compared to the balanced condition
(Hood et al. 2006). Klaassen et al. study (1998), including
15 volunteers, found a significant increase in CO2-induced
neurovegetative symptoms after ATD. In that study sample,
mean net increases in total PSL scores and VAAS scores
after CO2 were <7 and <7, respectively (Klaassen et al.
1998). Subjective CO2-induced anxiety was, therefore, very
mild, hence indicating that single-breath 35% CO2 in
healthy subjects did not evoke “real” panic. In the present
study, using double-breath CO2, we found a more than 30%
higher increase in PSL scores and more than 500% higher
increase in VAAS scores after CO2 compared to Klaassen et
al. (1998) study. Average VAAS and PSL scores in the
present double-breath 35% CO2 study are comparable to
those normally found in PD patients after single-breath
35% CO2 (Verburg et al. 1998). Other challenges in healthy
volunteers found no significant effect of ATD on responses
to anxiogenic challenges. This has been showed using a 5%
CO2 challenge (Miller et al. 2000) and the hypercapnic
Read rebreathing technique (Struzik et al. 2002), a
simulated public speaking challenge (Monteiro-dos-Santos
et al. 2000), and CCK-4 (Koszycki et al. 1996). In contrast,
a study by (Goddard et al. 1995) showed increased
nervousness in response to yohimbine challenge after
ATD compared to yohimbine alone.
To enhance 5-HT availability in healthy subjects, (Maron
et al. 2004) administered 5-HTP (direct precursor of 5-HT)
and used CCK-4 as panicogenic challenge in 32 healthy
volunteers. They observed a significant reduction compared
to placebo in CCK-4-induced panic attacks and cognitive
symptoms only in females, whereas in males only a
decrease in somatic symptoms was observed. In Schruers
et al. (2002b) study, 5-HTP did not alter the response to
35% CO2 compared to placebo. Taken together, these data
and our results indicate that the effects of Trp depletion in
healthy volunteers largely depend on the type of challenge
and its relative potency, and might be additionally con-
founded by gender effects.
Studies in PD patients demonstrated that ATD increased
the response to single-breath 35% CO2 (Schruers et al.
2000) and 5% CO2 anxiety (Miller et al. 2000), and
administration of 5-HTP blunted the response to single-
breath 35% CO2 (Schruers et al. 2002b)
ATD also increased the response to flumazenil infusion
in PD patients successfully treated with selective serotonin
reuptake inhibitors (SSRI) (Bell et al. 2002; Davies et al.
2006) or CBT (Bell et al. 2009). In contrast, subjective
response to CCK-4 is not influenced by ATD (Toru et al.
2006) in SSRI-treated PD patients. Also, ATD did not have
significant effects on the subjective response to anxiogenic
challenges in OCD (Barr et al. 1994; Kulz et al. 2007) and
in GAD SSRI-treated patients (Hood et al. 2010). It is
interesting to note that in the latest study of Hood and
colleagues (2010), using 7.5% CO2 challenge, some
subjective measures of anxiety (“something bad is going
to happen”, “anxious”, “secure”), seemed to indicate an
anxiolytic effect of ATD rather than anxiogenic; however,
pairways comparison was not significantly different be-
tween conditions.
As a further confirmation of the role of 5-HT in
modulating experimental panic, serotonergic drugs that are
effective in treating panic disorder, like SSRI and tryciclics,
also reduce the fear that patients with PD experience when
they inhale CO2 (Bertani et al. 2001; Bertani et al. 1997;
Perna et al. 2004; Perna et al. 2002; Perna et al. 1997; Pols
et al. 1996).
In summary, a number of studies in PD indicate that
availability of 5-HT precursors is inversely related to
vulnerability to CO2 challenges, which is at odds with the
present results. However, overall findings in anxiety
disorder patients suggest that the effects of Trp manipu-
lation specifically depend on the diagnosis and the type of
anxiogenic challenge.
Panic, 5-HT, and CO2: a complex relationship
Accumulating evidence from clinical and experimental
research and genetic studies suggest a substantial role for
the 5-HTsystem on the neurobiology of PD (see Maron and
Shlik 2006). The relationship between 5-HT and panic is
complex, as exemplified by the notion that SSRI are
effective in reducing panic, but they may exacerbate
anxiety during the initial phase of treatment (Sinclair et al.
2009). It has been hypothesized that panic is associated to
either 5-HT excess (Iversen 1984) and 5-HT deficit (Deakin
and Graeff 1991). Deakin & Graeff proposed that the 5-HT
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inhibiting panic responses, but contributing to anticipatory
or generalized anxiety. Our findings presented here are not
in line with this theory, as in our experimental design
increased 5-HT availability did not suppress CO2-induced
panic responses in healthy volunteers. However, recent
studies suggest that other factors should be taken into
account in understanding the relationship between 5-HT,
CO2 and anxiety: a subset of 5-HT neurons, located in the
chemosensitive zone (ventrolateral medulla and raphe) and
associated with large arteries, are intrinsically chemo-
sensitive in vitro (Severson et al. 2003) and are stimulated
by hypercapnia in vivo in unanaesthetized animals (Veasey
et al. 1995, 1997). Furthermore, experiments using in vivo
microdialysis showed that increasing inhaled CO2 causes an
increase in 5-HT release (Kanamaru and Homma 2007).
Interestingly, mice selectively lacking 5-HT neurons dis-
play a blunted respiratory response to CO2, indicating that
5-HT neurons are required for normal central chemorecep-
tion (Hodges and Richerson 2008). Richerson (2004)
proposed that medullary 5-HT neurons control ventilatory
responses to CO2 and project to areas like forebrain and
limbic system that are involved in affective regulation.
Taking into account the panicogenic properties of CO2,w e
have previously speculated that these neurons could be part
of an adaptive protective mechanism alerting the organism
against the risk of impending asphyxia (Griez et al. 2007).
Taken all these preclinical findings together, it appears that
acute hypercapnia stimulates serotonergic neurons and 5-
HT release and that conversely, disruption of the 5-HT
system blunts the neuronal response to CO2.
Our data are in line with the above preclinical evidence;
we have effectively reduced availability of 5-HT precursors
and we have used CO2 as a panicogenic challenge. In
agreement with Hodges and Richerson (2008) data, we
found that depletion of 5-HT precursors blunted the
subjective response to CO2, particularly the respiratory
sensations, and Trp availability was positively correlated
with the intensity of the subjective responses.
Methodological limitations
Some methodological considerations regard the validity of
Trp manipulations to alter 5-HT availability. Trp depletion
and Trp loading are relatively easy procedures to rapidly
and reversibly change, decrease and increase respectively,
the levels of 5-HT precursors (Hood et al. 2005). The first
step in 5-HT biosynthesis is the conversion of Trp to 5-HTP
by Trp hydroxylase. In the brain, this enzyme is only 50%
saturated and the rate at which 5-HT is synthesized is
limited only by substrate (Trp) availability. The LNAA
transport system at the blood–brain barrier has a high
affinity for all the LNAAs, including Trp. Therefore, the
ratio Trp:ΣLNAA in plasma is generally used to predict the
availability of Trp to the brain. A large body of literature
provides evidence that manipulations of the levels of Trp in
plasma results in a substantial and parallel alteration of 5-
HT synthesis in the brain and availability of 5-HT and its
metabolite in humans and animals (Biggio et al. 1974;
Carpenter et al. 1998; Gessa et al. 1974; Leathwood 1987;
Lieben et al. 2004; Williams et al. 1999). However, an
altered release of 5-HT efflux (thought to reflect synaptic
release, i.e., 5-HT neuronal activity) was only reported after
chronic Trp depletion (Fadda et al. 2000) or after ATD in
combination with 5-HT reuptake inhibition (Bel and
Artigas 1996), but not after ATD alone (van der Plasse et
al. 2007). In vitro studies suggest that an increase in Trp
availability determines dose-dependent changes in 5-HT
release under conditions of increased serotonergic neuronal
activity but not on basal output of 5-HT (Sharp et al. 1992;
Wolf and Kuhn 1986).
We assume that the alterations in the Trp:ΣLNAA ratio
of the present study were followed by changes in brain 5-
HT availability and synthesis in the same direction.
However, at present, we cannot assure that Trp depletion
and Trp loading actually influenced 5-HT release. Never-
theless, the possibility exists that the manipulations in the
present study did affect 5-HT neuronal release, based on the
abovementioned notions that acute hypercapnia stimulates
serotonergic neurons and induces 5-HT release, and that
Trp manipulations seem to be effective in altering 5-HT
release only in stimulated neurons.
A number of other methodological issues need to be
addressed. To manipulate brain Trp availability, the studies
in healthy volunteers of both Klaassen et al. (1998) and
Hood et al. (2006) included the use of the classic amino
acid mixture (Young et al. 1985), the former including an
addition of carbohydrates and fat. In these studies, ATD
appeared to be as effective as it was in ours and resulted in
a significant decrease of plasma Trp levels. However, the
magnitude of the depletion seems difficult to compare with
that in our study due to some methodological differences: in
the study of Klaassen et al. (1998), no baseline Trp plasma
levels were collected, and in the study of Hood et al.
(2006), free Trp plasma levels instead of total TRP levels
were used for calculation of the Trp:ΣLNAA ratio. It is still
debated whether total Trp or free Trp levels in plasma are
the most reliable indirect measures of brain Trp availability
(Pardridge 1998). Therefore, methodological differences
might account for the divergent findings in our study
compared to previous studies in healthy volunteers.
Conclusions
It is recognized that 5-HT system plays a complex role in
the regulation of the panic responses to CO2, as different
746 Psychopharmacology (2011) 215:739–748serotonergic mechanisms can coexist, either inhibiting
panic (Deakin and Graeff 1991) or promoting the aversive
respiratory sensations to hypercapnic stimuli. The differ-
ences observed in our study in healthy volunteers,
compared to previous findings in PD patients, might
depend on the different relative contribution of these
mechanisms in different populations.
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